Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1.

Kallander LS, Washburn D, Hilfiker MA, Eidam HS, Lawhorn BG, Prendergast J, Fox R, Dowdell S, Manns S, Hoang T, Zhao S, Ye G, Hammond M, Holt DA, Roethke T, Hong X, Reid RA, Gampe R, Zhang H, Diaz E, Rendina AR, Quinn AM, Willette B.

ACS Med Chem Lett. 2018 Jul 2;9(7):736-740. doi: 10.1021/acsmedchemlett.8b00173. eCollection 2018 Jul 12.

2.

4,6-Diaminopyrimidines as Highly Preferred Troponin I-Interacting Kinase (TNNI3K) Inhibitors.

Philp J, Lawhorn BG, Graves AP, Shewchuk L, Rivera KL, Jolivette LJ, Holt DA, Gatto GJ Jr, Kallander LS.

J Med Chem. 2018 Apr 12;61(7):3076-3088. doi: 10.1021/acs.jmedchem.8b00125. Epub 2018 Mar 21.

PMID:
29561151
3.

Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition.

Lawhorn BG, Tran T, Hong VS, Morgan LA, Le BT, Harpel MR, Jolivette L, Diaz E, Schwartz B, Gross JW, Tomaszek T, Semus S, Concha N, Smallwood A, Holt DA, Kallander LS.

Bioorg Med Chem Lett. 2017 Nov 1;27(21):4838-4843. doi: 10.1016/j.bmcl.2017.09.046. Epub 2017 Sep 23.

PMID:
28985999
4.

Substituent Effects on Drug-Receptor H-bond Interactions: Correlations Useful for the Design of Kinase Inhibitors.

Lawhorn BG, Philp J, Graves AP, Holt DA, Gatto GJ Jr, Kallander LS.

J Med Chem. 2016 Dec 8;59(23):10629-10641. Epub 2016 Nov 22.

PMID:
27933961
5.

GSK114: A selective inhibitor for elucidating the biological role of TNNI3K.

Lawhorn BG, Philp J, Graves AP, Shewchuk L, Holt DA, Gatto GJ Jr, Kallander LS.

Bioorg Med Chem Lett. 2016 Jul 15;26(14):3355-3358. doi: 10.1016/j.bmcl.2016.05.033. Epub 2016 May 14.

PMID:
27246618
6.

Identification of Purines and 7-Deazapurines as Potent and Selective Type I Inhibitors of Troponin I-Interacting Kinase (TNNI3K).

Lawhorn BG, Philp J, Zhao Y, Louer C, Hammond M, Cheung M, Fries H, Graves AP, Shewchuk L, Wang L, Cottom JE, Qi H, Zhao H, Totoritis R, Zhang G, Schwartz B, Li H, Sweitzer S, Holt DA, Gatto GJ Jr, Kallander LS.

J Med Chem. 2015 Sep 24;58(18):7431-48. doi: 10.1021/acs.jmedchem.5b00931. Epub 2015 Sep 10.

PMID:
26355916
7.

Inhibition of the cardiomyocyte-specific kinase TNNI3K limits oxidative stress, injury, and adverse remodeling in the ischemic heart.

Vagnozzi RJ, Gatto GJ Jr, Kallander LS, Hoffman NE, Mallilankaraman K, Ballard VL, Lawhorn BG, Stoy P, Philp J, Graves AP, Naito Y, Lepore JJ, Gao E, Madesh M, Force T.

Sci Transl Med. 2013 Oct 16;5(207):207ra141. doi: 10.1126/scitranslmed.3006479.

8.

Improving the developability profile of pyrrolidine progesterone receptor partial agonists.

Kallander LS, Washburn DG, Hoang TH, Frazee JS, Stoy P, Johnson L, Lu Q, Hammond M, Barton LS, Patterson JR, Azzarano LM, Nagilla R, Madauss KP, Williams SP, Stewart EL, Duraiswami C, Grygielko ET, Xu X, Laping NJ, Bray JD, Thompson SK.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):371-4. doi: 10.1016/j.bmcl.2009.10.092. Epub 2009 Oct 25.

PMID:
19926282
9.

The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophages.

Marino JP Jr, Kallander LS, Ma C, Oh HJ, Lee D, Gaitanopoulos DE, Krawiec JA, Parks DJ, Webb CL, Ziegler K, Jaye M, Thompson SK.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5617-21. doi: 10.1016/j.bmcl.2009.08.036. Epub 2009 Aug 13.

PMID:
19717304
10.

4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo.

Kallander LS, Lu Q, Chen W, Tomaszek T, Yang G, Tew D, Meek TD, Hofmann GA, Schulz-Pritchard CK, Smith WW, Janson CA, Ryan MD, Zhang GF, Johanson KO, Kirkpatrick RB, Ho TF, Fisher PW, Mattern MR, Johnson RK, Hansbury MJ, Winkler JD, Ward KW, Veber DF, Thompson SK.

J Med Chem. 2005 Sep 8;48(18):5644-7.

PMID:
16134930
11.

Discovery of non-steroidal mifepristone mimetics: pyrazoline-based PR antagonists.

Jones DG, Liang X, Stewart EL, Noe RA, Kallander LS, Madauss KP, Williams SP, Thompson SK, Gray DW, Hoekstra WJ.

Bioorg Med Chem Lett. 2005 Jul 1;15(13):3203-6.

PMID:
15925510
12.

A Versatile Enantioselective Strategy Toward L-C-Nucleosides: A Total Synthesis of L-Showdomycin.

Trost BM, Kallander LS.

J Org Chem. 1999 Jul 23;64(15):5427-5435.

PMID:
11674603
13.

Supplemental Content

Loading ...
Support Center